Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 8, 2004, Pages 602-612

  Heuzenroeder, Louise ^b   Donnelly, Marie ^a   Haby, Michelle M ^a   Mihalopoulos, Cathrine ^c   Rossell, Ruth ^d   Carter, Rob ^c   Andrews, Gavin ^d   Theo, V ^a  

^a Public Health   (Australia)

^b Victorian Public Health Training Scheme   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antidepressive agents; Anxiety disorders; Cognitive behaviour therapy; Cost effectiveness; Meta analysis

Indexed keywords

IMIPRAMINE; PAROXETINE; VENLAFAXINE;

ARTICLE; AUSTRALIA; BEHAVIOR THERAPY; CALCULATION; CLINICAL TRIAL; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PANIC; PSYCHOLOGIST; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; AUSTRALIA; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DISABILITY EVALUATION; HUMANS; IMIPRAMINE; MENTAL HEALTH SERVICES; PANIC DISORDER; PAROXETINE; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 4444220375     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01423.x     Document Type: Article

References (45)

1. Mathers CD, Vos T, Stevenson C. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare, 1999.
2. Vanin JR, Vanin SK. Blocking the cycle of panic disorder. Postgraduate Medicine 1999; 105:141-146.
3. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: Switzerland, 1992.
4. Australian Bureau of Statistics. Mental health and wellbeing: profile of adults, Australia 1997. Canberra: Australian Bureau of Statistics, 1998.
5. Therapeutic Guidelines Limited. Therapeutic guidelines: psychotropic. 4th edn. Melbourne: Therapeutic Guidelines Limited, 2000.
6. Britt H, Miller G, Knox S et al. General practice activity in Australia 2000-01. General Practice Series No. 8. Canberra: Australian Institute of Health and Welfare, 2001.
7. Kapczinski F, Schmitt R, Lima M. The use of antidepressants for generalized anxiety disorder. In: The Cochrane Library,: Issue 2. Oxford: Update Software.
8. Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. Journal of Clinical Psychiatry 2001; 62(Suppl. 19):26-31.
9. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 2000; 283:3082-3088.
10. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 2000; 157:968-974.
11. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Journal of Clinical Psychiatry 2001; 62:523-529.
12. Pollack MH, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 2001; 62:350-357.
13. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica 1997; 95:444-450.
14. Rudolph L, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. Journal of Clinical Psychopharmacology 1998; 18:136-144.
15. Caswell A ed. MIMS Sydney: MediMedia Australia, 2001.
16. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Australian and New Zealand Journal of Psychiatry 2003; 37:641-656.
17. Haby M, Carter R, Mihalopoulos C, Magnus A, Andrews G, Vos T. Assessing Cost-Effectiveness - Mental Health: introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004; 38:569-578.
18. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release ER in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 2001; 179:15-22.
19. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 1999; 60:528-535.
20. Australian Bureau of Statistics. Census data 2000: population by age and sex, Australian states and territories. Time series spreadsheet, 32010.0: Table 9. Canberra: Australian Bureau of Statistics, 2001.
21. Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatrica Scandinavica 1991; 84:446-452.
22. Keller M. The long-term clinical course of generalised anxiety disorder. Journal of Clinical Psychiatry 2002; 63(Suppl. 8): 11-16.
23. Yonkers K, Dyck I, Warwhaw M, Keller M. Factors predicting the clinical course of generalised anxiety disorder. British Journal of Psychiatry 2000; 176:544-549.
24. Stouthard M, Essink-Bot M, Bonsel G et al. Disability weights for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, 1997.
25. Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health states. Quality of Life Research 2004; 13:in press.
26. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clinical Psychological Review 1995; 15:819-844.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV) 4th edn. Washington, DC: American Psychiatric Press, 1994.
28. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal Consulting and Clinical Psychology 1993; 61:611-619.
29. Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology 1991; 59:167-175.
30. Durham RC, Murphy T, Allan T, Richard K, Treliving LR, Fenton GW. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. British Journal of Psychiatry 1994; 165:315-323.
31. Ladouceur R, Dugas M, Freeston M, Gagnon F, Thibodeau N. Efficacy of a cognitive behavioural treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. Journal of Consulting Clinical Psychology 2000; 68:957-964.
32. White J, Keenan M. Stress control: a controlled comparative investigation of large group therapy for generalized anxiety disorder. Behavioural Psychotherapy 1992; 20:97-114.
33. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith G, Altman D eds. Systematic reviews in health care: meta-analysis in context, 2nd edn. London: BMJ Publishing Group, 2001; 285-312.
34. Drummond M, McGuire A eds. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001.
35. Palisade Corporation. RISK [computer program] Risk Analysis Add-in for Microsoft Excel, Version 4. Newfield, NY: Palisade Corporation, 2001.
36. Otto MW, Pollack M, Maki KM. Empirically supported treatments for panic disorder: costs, benefits and stepped care. Journal of Consulting and Clinical Psychology 2000; 68:556-563.
37. Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H. Modelling the population cost-effectiveness of current and evidence based optimal treatment for anxiety disorders. Psychological Medicine 2004; 34:19-35.
38. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. International Clinical Psychopharmacology 2000; 15:99-105.
39. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. British Journal of Psychiatry 1999; 174:213-218.
40. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatrica Scandinavica 2001; 104:289-298.
41. de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatrica Scandinavica 1999; 99:59-67.
42. Lader MH, Bond AJ. Interaction of pharmacological and psychological treatments of anxiety. British Journal of Psychiatry 1998; (Suppl.):42-48.
43. Perry S. Combining antidepressants and psychotherapy: rationale and strategies. Journal of Clinical Psychiatry 1990; 51 (Suppl.): 16-20.
44. Mental Health and Suicide Prevention Branch. Better outcomes in mental health care initiative. Canberra: Australian Department of Health and Ageing, 2002. (Available at: http://www.health.gov.au/hsdd/mentalhe/boimhc/index.htm Last accessed 12 November 2003.)
45. Selmi P, Klein M, Greist J, Sorrell S, Erdman H. Computer-administered cognitive-behavioural therapy for depression. American Journal of Psychiatry 1990; 147:51-56.